Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | PTGER4 | P35408 | 8/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | B3GNT2 | Q9NY97 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6239877 | 0.92 | RXFP1 (0.41) | RXFP1POLBPTGER4ALDH1A1KDM4E | |
| SCHEMBL6236005 | 0.92 | B3GNT2 (0.46) | RXFP1TRPA1MMP13PTGER4ALDH1A1 | |
| SCHEMBL6232987 | 0.91 | MAPT (0.48) | RXFP1MMP13PTGER4ALDH1A1SMN1; SMN2 | |
| SCHEMBL6238348 | 0.91 | DCLK1 (0.47) | RXFP1PTGER4ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL6233970 | 0.90 | TRPA1 (0.41) | RXFP1TRPA1MMP13PTGER4ALDH1A1 | |
| SCHEMBL6238762 | 0.90 | EPHX2 (0.41) | RXFP1PTGER4ALDH1A1SMN1; SMN2EPHX2 | |
| SCHEMBL6236399 | 0.89 | CA2 (0.42) | EPHX2NR1H4 | |
| SCHEMBL6462193 | 0.88 | MLYCD (0.40) | MMP13PTGER4ALDH1A1KDM4EPTGER2 | |
| SCHEMBL6272724 | 0.88 | NR1H4 (0.47) | RXFP1SMN1; SMN2LMNAEPHX2NR1H4 | |
| SCHEMBL6232757 | 0.85 | ROCK2 (0.41) | MMP13PTGER4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030004172-A1 | Fused pyrimidinone matrix metalloproteinase inhibitors | HARTER WILLIAM GLEN (US) | 2003-01-02 | — | — | US | claimed |
| EP-1530467-A2 | COMBINATION OF AN ALLOSTERIC CARBOXYLIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 WITH CELECOXIB OR VALDECOXIB | Warner-Lambert Company LLC (US) | 2005-05-18 | — | — | EP | disclosed |
| WO-2004006912-A2 | COMBINATION OF AN ALLOSTERIC CARBOXYLIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 WITH CELECOXIB OR VALDECOXIB | WARNER-LAMBERT COMPANY LLC (US) | 2004-01-22 | — | — | WO | disclosed |
| EP-1370562-A1 | THIENO[2,3-D]PYRIMIDINDIONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2003-12-17 | — | — | EP | disclosed |
| EP-1287192-A1 | METHOD FOR PRODUCING SYNTHETIC FIBRES FROM A FIBRE-FORMING POLYMER-BASED MELT BLEND | Röhm GmbH & Co. KG (DE) | 2003-03-05 | — | — | EP | disclosed |
| US-20030004172-A1 | Fused pyrimidinone matrix metalloproteinase inhibitors | HARTER WILLIAM GLEN (US) | 2003-01-02 | — | — | US | disclosed |
| WO-2002064598-A1 | THIENO'2,3-D PYRIMIDINDIONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | disclosed |
| WO-2001090454-A1 | METHOD FOR PRODUCING SYNTHETIC FIBRES FROM A FIBRE-FORMING POLYMER-BASED MELT BLEND | Röhm GmbH & Co. KG (DE) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004172-A1 | Fused pyrimidinone matrix metalloproteinase inhibitors | MMP13, MMP3, MMP25 | RXFP1 173/4885TRPA1 3888/4885POLB 966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.